Why is Concord Biotech falling/rising?

As of 09-Sep, Concord Biotech Ltd is experiencing a decline in its stock price, currently at Rs 1,585.00, which reflects a decrease of Rs 28.2 or 1.75%. The stock has been underperforming, having fallen for six consecutive days, resulting in a total decline of 6.38% during this period. Today's performance indicates that it has underperformed its sector by 2.38%, with an intraday low of Rs 1,575. The stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, and there has been a significant drop in investor participation, with delivery volume decreasing by 38.81% compared to the 5-day average. Additionally, the company's recent financial performance shows concerning trends, including a 52.6% drop in PAT and the lowest quarterly net sales and PBDIT figures, which contribute to a negative outlook.
In the broader market context, Concord Biotech's recent performance contrasts sharply with the Sensex, which has gained 1.18% over the past week and 1.56% over the past month. The stock has generated a return of -28.28% year-to-date, while the benchmark has increased by 3.79% in the same timeframe. This underperformance is compounded by a high Price to Book Value ratio of 9.1, indicating that the stock is trading at a premium compared to its peers, despite a relatively low debt-to-equity ratio and high management efficiency. Furthermore, the decline in institutional investor participation, with a 0.54% reduction in stakes, suggests a lack of confidence in the company's long-term growth potential, which is reflected in its poor performance metrics.